Biotech Co.*
(Country; Symbol)

Pharma Co.
(Country)

Type/Product Area

Terms/Details (Date)


AdipoGenix  
Inc.*
 

Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson)

Agreement to develop
anti-obesity compounds through use of AdipoGenix's technology
to control fatty acid accumulation

AdipoGenix will screen compounds belonging to Johnson & Johnson, in return for an up-front payment, as well as milestone payments, licensing fees and royalties (12/16)

 

Albany Molecular Research Inc.
(AMRI)

Takeda Chemical Industries Ltd.
(Japan)

Renewable one-year pharmaceutical research and development collaboration for small- molecule drugs

AMRI will conduct chemistry research to identify and develop small-molecule drug candidates against a Takeda target; AMRI will receive fees, and possibly milestone and royalty payments (11/26)

 

Algen Bio- pharmaceuticals* (Israel)

Kirin Brewery Company Ltd.
(Japan)

Agreement in which Kirin will invest an initial US$5M in a joint venture with Algen, in exchange for rights to commercialize the technology

Algen was formed based on Hebrew University's discoveries on how to "trick" cancer cells into activating the protein PKR in cancer cells without activating it in normal cells, and thus fine-tuning selective cell death (12/11**)

 

Amgen Inc.
(AMGN)

Serono SA (Switzerland)

Novantrone

Agreement allowing Serono to sell Novantrone in the U.S. (11/13)

 

AnorMED 
Inc.
(Canada; 
TSE:AOM)

Bristol-Myers Squibb Medical Imaging Inc. (unit of Bristol-Myers Squibb Co.)

Licensing agreement for AnorMED's Hynic linker technology for the commercial development of products to be used for diagnostic medical imaging of cardiovascular diseases

AnorMED will receive a nonrefundable, upfront payment of US$0.1M, as well as annual payments ending in 2007; AnorMED also would receive milestone payments upon U.S. approval of new drug applications, as well as a royalty based on sales of products that incorporate the technology (12/10)

 

Antisoma plc  
(UK; LSE:ASM)

F. Hoffmann-La Roche Ltd. (Switzerland)

Agreement for four Antisoma products currently in clinical trials and an option on all compounds that reach the clinic in the next five years

Roche will cover the remaining development costs of pemtumomab and Therex; the deal is worth US$500M, including up- front payments of $43M (11/18)

 

Ardais Corp.*

Bristol-Myers
Squibb Co.

Licensing agreement to access Ardais' BIGR Library and Suite of Bioinformatics Tools

Financial terms and other details were not disclosed (11/19)

 

Ariad Pharmaceuticals Inc. (ARIA)  

Bristol-Myers
Squibb Co.

Nonexclusive worldwide license agreement giving BMS the right to conduct pharmaceutical research  and development covered by Ariad's NF-(kappa)B patents.

Ariad will receive an up-front license fee and annual license fees, and could receive milestone payments (11/6)

 

Avera Pharmaceuticals Inc.*

Eli Lilly 
and Co.

Licensing agreement for a compound that offers promise for the treatment of major mental illnesses such  as depression, schizophrenia and cognitive disorders

Avera acquired the worldwide rights to the compound and supporting intellectual property in exchange for up-front, milestone and royalty payments (12/17)

 

Berna Biotech  
AG
(Switzerland; SWX:BBIN)

Shire Pharmaceuticals Group plc (UK)

Hepavax Gene, Bio-Hep-B 
and Fluviral

Shire receives exclusive European rights for the commercialization of Berna Biotech's hepatitis B vaccines; Berna receives exclusive rights for the commercialization of Shire's influenza vaccine, Fluviral, in territories outside North America and Europe; profits will be shared equally (11/6**)

 

Beyond  
Genomics 
Inc.*

GlaxoSmithKline
plc (UK)

Agreement in which the companies will apply Beyond Genomics' Systems Biology approach to elucidate  disease pathways and identify protein and metabolite markers of disease states and drug response

The goal is to better understand proteins and metabolites that might play roles in mediating disease states and response to drugs (12/11)

 

Cambridge
Antibody
Technology Group plc (UK; CATG; LSE:CAT)

Merck & Co. 
Inc.

Agreement giving Merck a 
license to CAT's human phage antibody libraries, which will be used by Merck to support and promote discovery research and development

CAT will receive an up-front license fee, including a technology access fee upon transfer of the libraries to Merck; CAT could receive future option, milestone and royalty payments from Merck, which gets option rights to develop therapeutic and diagnostic products on an exclusive basis (10/30)

 

Cell  
Therapeutics
 
Inc.
(CTIC)

Nippon Shinyaku
Co. Ltd. (Japan)

Trisenox

Agreement in which Nippon will market and distribute Trisenox in Japan, South Korea and Taiwan; Cell Therapeutics could receive milestone payments of $1.75M for regulatory approval of Trisenox in those countries for the relapsed acute promyelocytic leukemia indication; there is $3M committed to milestones in other hematologic malignancies, as well as milestone payments for Trisenox approval in additional indications (12/17)

 

Cellular  
Genomics 
Inc.*

Schering AG
(Germany)

Agreement under which 
Cellular Genomics will apply its chemical genetics technologies to an undisclosed target kinase selected by Schering

Cellular Genomics will receive an undisclosed up-front fee and a series of mile- stone payments over 15 months (12/12)

 

ChemBridge Research Laboratories  
LLC
*

Genomics Institute of the Novartis Research Foundation (an affiliate of Novartis AG; Switzerland)

Three-year discovery 
chemistry agreement

ChemBridge will provide nonexclusive access to its GPCR-Targeted Library consisting of small molecules based on nonpeptide chemotypes; the foundation will provide certain screening data to ChemBridge relating to the provided compounds (12/10)

 

CollaGenex Pharmaceuticals Inc. (CGPI)

Medtronic Inc.

Agreement to explore the 
use of CollaGenex's IMPACS compounds in combination with medical devices

Medtronic will get an exclusive, worldwide license to technology relating to the use of the IMPACS to treat aortic aneurysms and other forms of vascular disease with medical devices (10/21)

 

Compugen 
Ltd.
(Israel; 
CGEN)

NV Organon (the Netherlands) and Procter & Gamble Co.

Licensing agreement for Compugen's Z40000 fully automated system for designing, analyzing and controlling large-scale 2-D gel experiments for proteomics research

Further details were not disclosed (11/6)

 

Corixa Corp.
(CRXA)

Kirin Brewery 
Co. Ltd. (Japan)

Collaboration to develop a product against multiple forms of cancer

Kirin has rights to develop and market vaccine products in Asia/Australasia using Corixa's Wilms' tumor antigen vaccine program; the companies will share rights in North America, as well as development and commercialization costs; Corixa retains rights in Europe; Corixa will get $3M up front, as well as potential milestone payments and royalties (12/5)

 

CuraGen Corp.
(CRGN)

Mitsubishi 
Pharma Corp.
(Japan)

Collaboration on 
schizophrenia drug targets

The deal does not include a lot of money up front, but has the potential downstream with CuraGen's target validation capabilities (11/5)

 

Curis Inc.  
(CRIS)

Ortho Biotech
Products LP 
(unit of Johnson 
& Johnson)

Licensing agreement for 
Curis' bone morphogenetic protein portfolio

The portfolio includes BMP-7, and Ortho gets rights for all indications except for the repair or regeneration of local musculoskeletal tissue defects and dental defects; Curis receives $3.5M up front in the deal, as well as milestone payments and an undisclosed royalty rate on product sales (11/27)

 

DeCode  
genetics Inc.
(Iceland; DCGN)

Wyeth

Agreement in which DeCode 
will use its in vitro pharmacogenomics knowledge to generate gene expression data related to one of Wyeth's candidate drugs

Financial terms were not disclosed (11/20)

 

Domantis 
Ltd.*
(UK)

Abbott Laboratories

Research and license agreement to discover multiple therapeutic pro- ducts based on Domantis' Domain Antibody technology

The agreement calls for the companies to collaborate on the identification and optimization of Domain Antibodies to the first two undisclosed Abbott therapeutic targets, and provides Abbott with nonexclusive access to the Domain Antibody technology for use with additional therapeutic targets; Domantis will receive funding for collaborative research activities and license fees for technology access; Domantis also could receive more license fees and development milestones, as well as royalties on sales (11/4)

 

DxS Ltd.*  
(UK) & Johnson)

Ortho-Clinical Diagnostics Inc. (unit of Johnson  

Licensing agreement and research collaboration for DxS' Scorpions nucleic acid detection technology

The license gives nonexclusive rights to use the Scorpions technology in the development of cancer diagnostics (11/6**)

 

Enzon Inc.  
(ENZN)

Elan Corp. 
plc (Ireland)

Abelcet

Agreement in which Elan sold to Enzon its U.S., Canadian and Japanese rights to Abelcet and certain related assets for $360M (11/12)

 

Ethypharm 
SA*
(France)

Conba Pharmaceutical (China)

Research and development agreement with the goal of developing enhanced Chinese medicines using Ethypharm's oral controlled- release and Fast Melt Flashtab technologies

Ethypharm will contribute its technologies, while Conba will invest US$2M in cash; the companies also signed a multiproduct development agreement worth US$1.2M under which they will collaborate to develop and register new Chinese medicine preparations using several patents and technologies of Ethypharm for the Chinese market (11/25)

 

Exelixis Inc.
(EXEL)

GlaxoSmithKline
plc (UK)

Collaboration to develop therapeutics in the vascular biology, inflammatory  disease and oncology areas using Exelixis' drug candidates

The deal carries guaranteed funding of $134M, a loan facility of $85M and milestones and royalties (10/29)

 

Eyetech Pharmaceuticals Inc.*

Pfizer Inc.

Agreement for the development and commercialization of Macugen for age-related macular degeneration and diabetic macular edema

Pfizer will pay Eyetech a $100M upfront fee, with the potential for an additional $195M in milestone payments on world- wide regulatory submission and approval, as well as $450M in milestone payments upon successful commercialization and reaching certain sales levels; Pfizer also will fund development costs; the companies would co-promote the drug in the U.S., and Pfizer would market it outside the U.S. under a royalty-bearing license (12/18)

 

Genaera 
Corp.
(GENR)

E.I. du Pont 
de Nemours 
and Co.

Option agreement for certain antimicrobial peptide intellectual property held by Genaera

The option is in place for up to three years from October and provides reimbursement to Genaera for patent-related expenses (11/20)

 

Genaissance Pharmaceuticals Inc. (GNSC)

Pharmacia 
Corp.

Pharmacogenomics-based agreement in which Genaissance will apply its HAP technology to clinical trial samples from Pharmacia

Financial terms were not disclosed (12/17)

 

Gene Logic 
Inc.
(GLGC)

F. Hoffmann-
La Roche Ltd. (Switzerland)

Agreement to purchase a customized GeneExpress database to augment Roche's drug development efforts

The product will contain current gene expression data selected by Roche researchers from the GeneExpress database (12/12)

 

Genfit SA*
(France)

Kowa Co. 
(Japan)

Research collaboration agreement aimed at the development of a new anti-atherosclerotic drug based on research carried out by Genfit into a natural  mechanism that eliminates cholesterol from arterial walls

The deal is for five years and calls for Kowa to make an up-front payment to Genfit for the purchase of a license and to provide it with annual research funding, as well as potential milestone and royalty payments (11/13**)

 

GenVec Inc.
(GNVC)

Fuso Pharmaceutical Industries Ltd. (Japan)

Three-year agreement to identify a targeted cancer therapy product candidate designed to treat not only a primary tumor, but also cancer that has spread to distant sites in the body

The deal is worth $4.5M; GenVec retains worldwide rights, excluding Japan, to develop and commercialize product candidates; Fuso keeps rights in Japan and an option to commercialize in Korea and Taiwan; the agreement includes development milestone and royalty payments; each party is responsible for development and commercialization costs in its respective territories (12/11)

 

Heska Corp.
(HSKA)

Pharmacia Diagnostics 
(unit of Pharmacia Corp.)

Agreement giving Pharmacia a worldwide exclusive license to develop and commercialize Heska's recombinant allergen  intellectual property for human allergy diagnostic use

The license covers a range of unnamed recombinant allergens; Heska will receive license fees, and could receive milestone payments and royalties (12/3)

 

Human Genome Sciences Inc.
(HGSI)

Kirin Brewery Company Ltd.
(Japan)

Licensing agreement centered 
on a protein discovered by Human Genome Sciences

The agreement is focused on agonistic human monoclonal antibodies to tumor necrosis factor apoptosis-inducing ligand receptor-2; the companies will identify and optimize the best candidate for clinical development (12/3)

 

Isis Pharmaceuticals Inc. (ISIS)

GlaxoSmithKline
plc (UK)

Target validation agreement centered on Isis' GeneTrove division

GSK will focus on functionalizing and validating gene targets, using Isis' antisense inhibitors, and it will take a license to Isis' intellectual property for its internal anti- sense-based functional genomics program (12/11)

 

Luminex 
Corp.
 
(LMNX)

Bayer Diagnostics (division of Bayer Corp.)

License agreement and supply agreement for Luminex's xMAP technology, as well as a multiyear agreement relating to the development of a new cellular analyzer

The license agreement grants Bayer the right to develop and distribute in vitro diagnostic products based on Luminex's xMAP technology; Bayer Diagnostics will pay Luminex a one-time nonrefundable license fee; Luminex also would receive royalties from any products that result (11/11)

 

MerLion Pharmaceuticals Pte. Ltd.* (Singapore)

Abbott Laboratories

Collaboration on the discovery of natural product-based drugs for use in a range of therapeutic areas, including oncology, metabolics, antivirals, immunology and neuroscience

Abbott will contribute a number of targets for MerLion to screen against its sample collection; Abbott will perform lead optimization, development and marketing of products; MerLion will receive research and milestone payments and royalties (11/26)

 

Metabasis Therapeutics 
Inc.*

Sankyo Co. 
Ltd. (Japan)

Exclusive option agreement to develop a second-generation gluconeogenesis inhibitor to treat Type II diabetes

The deal could be worth between $25M and $50M; the companies already are developing CS-917, a first-generation gluconeogenesis inhibitor (10/29)

 

Microbix Biosystems 
Inc.
(Canada; TSE:MBX)  

Undisclosed pharmaceutical company

Agreement for worldwide rights to Microbix's lead biotherapeutic drug, ThromboClear, a generic version of Abbokinase

Microbix is to receive a royalty rate of 35% of the gross margin, and the partner will assume responsibility and all costs for commercializing ThromboClear (11/19)

 

Molecular 
Mining
Corp.*

GlaxoSmithKline
plc (UK)

Collaboration to analyze gene expression data in order to learn more about mechanisms underlying bone formation

The deal involves analysis of gene expression over time in bone tissues containing different cell types that have been subjected to treatments known to stimulate bone formation (12/2)

 

Morphochem 
AG*
(Germany)

AstraZeneca 
AB (Sweden)

Agreement wherein Morphochem will apply its MORE system technology to the discovery of compounds with activity against an  undisclosed target in the area of thrombolytic disorders

Morphochem will apply its evolutionary discovery approach that uses multicomponent reaction chemistry along with software based on genetic algorithms; AstraZeneca will fund the research (11/21)

 

Neose Technologies  
Inc.
(NTEC)

Novo Nordisk 
A/S (Denmark)

Research and development collaboration focusing on the use of Neose's GlycoPEGylation technology

The technology will be used to make potentially clinically significant improvements to a Novo therapeutic protein (10/30)

 

Neurogenetics
Inc.*
 

Eisai Co. Ltd.
(Japan)

Research agreement focusing on the discovery of genes responsible for late-onset Alzheimer's disease to establish valid targets and to facilitate the development of new therapeutic products

Neurogenetics received a signing fee, an equity investment and research support for three years; Eisai gained rights of first negotiation and refusal for biologically validated targets identified in the collaboration (10/24)

 

NeuroSearch  
A/S*
(Denmark)

GlaxoSmithKline
plc (UK)

Collaboration focused on the discovery and development of mixed monoamine reuptake inhibitors for treatment of depression and other mood disorders

NeuroSearch could receive up to US$27M in milestone payments, plus product royalties, on the first compound derived from the program that reaches the market; it would receive additional milestones and royalties on subsequent molecules that enter clinical development (11/25)

 

Pharmagene 
plc
(UK; LSE:
PGN)

Shionogi & Co.
Ltd. (Japan)

Agreement for access to Pharmagene's target and compound validation capabilities, TargetEvaluator and Phase Zero

Financial details were not disclosed (10/30)

 

Renovis 
Inc.*

Centaur Pharmaceuticals
Inc.

Agreement in which Renovis acquired the assets of Centaur 
for $1.25M in cash and up to 30% of Renovis stock

The acquired assets include NXY-059 for acute stroke, REN-1189 for neuropathic pain, several preclinical compounds and a compound library (12/12)

 

Response Genetics Inc.*

Eli Lilly and Co.

Pharmacogenomics research agreement in which Response Genetics will provide gene expression data to Lilly from paraffin-reserved tumor tissue treated with Lilly compounds

Financial terms were not disclosed (10/28)

 

Ricerca Biosciences 
LLC*

Eli Lilly and Co.

Agreement giving Ricerca rights to Lilly's small-molecule antibacterial targets and patents

Ricerca will own rights to develop and commercialize drugs based on the antibacterial targets; Lilly will receive an up-front payment, as well as royalty and milestone payments for any drugs and drug candidates developed (12/4)

 

Saegis Pharmaceuticals Inc.*

Eli Lilly and Co.

Licensing agreement for a preclinical compound to be developed to treat cognitive impairment

Saegis will be responsible for filing an investigational new drug application and Lilly has an option to buy back the compound after the completion of a Phase II trial (10/28)

 

Scimagix Inc.*  

F. Hoffmann-La Roche Ltd. (Switzerland)

Multiyear agreement to jointly develop and implement image data management solutions supporting Roche's proteomics processes

Scimagix will provide Roche with the technology to analyze, integrate and track experimental data relating to protein expression (12/12)

 

Scynexis Inc.*  

F. Hoffmann-La Roche Ltd. (Switzerland)

Research collaboration to discover and develop compounds for central nervous system and metabolic diseases

Roche will receive exclusive worldwide rights to resulting products in exchange for up-front technology access fees and other compensation for services (11/14)

 

Serenex Inc.*

Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson)

Agreement for Serenex to use its Proteome Mining technology to uncover new drug targets

The objective is to evaluate Serenex's technology to identify drug compounds that interact with pharmaceutically important protein targets to uncover the new drug targets (10/29)

 

Serono SA (Switzerland; NYSE:SRA)

IVAX Corp.

Agreement to develop IVAX's cladribine as an oral treatment for multiple sclerosis

IVAX will receive milestone and royalty payments on sales of any approved product; further financial terms were not disclosed (10/30)

 

Triad  
Therapeutics
 
Inc.*

Schering-Plough Research Institute (unit of Schering-Plough Corp.)

Research collaboration to discover novel compounds with antifungal activity

Schering-Plough will supply the targets and Triad will screen them against its existing collection of compounds; Schering-Plough will pay an initiation fee and could make additional payments, including royalties (12/10)

 

Vectura Ltd.*
(UK)

GlaxoSmithKline
plc (UK)

Agreement to evaluate 
Vectura's Aerocine and associated powder formulation technologies in dry powder inhaler devices for the treatment of inflammatory and constrictive diseases of the airway

Further details were not disclosed (12/4)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies. It includes a collaboration that occurred before Oct. 24th. but that was not listed in the previous chart.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange